CAR T-cell Consolidation Versus Lenalidomide Maintenance after Autologous Stem Cell Transplant in Multiple Myeloma: A Comparative Analysis of Toxicity and Cost

Key Points

• CAR T-cell consolidation shows a notable difference in toxicity compared to lenalidomide maintenance, influencing treatment decisions.
• The analysis revealed that CAR T-cell therapy incurs higher costs relative to lenalidomide post-autologous stem cell transplant.
• Observational analysis across multiple myeloma patient cases highlights varying responses to CAR T-cell and lenalidomide interventions.
• Understanding cost and toxicity trade-offs may enable informed treatment choices in multiple myeloma management.